Press Release
bit.bio presents data at ISSCR
The posters demonstrate the capability of opti-ox technology to create any human cell.
15.06.2022News
Press Release
bit.bio wins two awards at Cambridge Independent Science and Tech Awards
bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.
Press Release
bit.bio launches Huntington’s disease human cell model
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
Article
Rahul Singhvi, CEO National Resilience Inc. visits bit.bio labs
We were delighted to welcome CEO National Resilience Inc. Rahul Singhvi who visited our labs and office space.
Press Release
bit.bio appoints Kathryn Corzo as Chief Operating Officer
bit.bio appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.
Press Release
bit.bio signs up to race to zero as part of COP26
The pledge is part of our mission to code cells for novel cures and to be a purpose led company.
Press Release
bit.bio raises $103 million in first close of Series B financing
Funding raised to accelerate and expand cell therapy pipeline.
Press Release
New product launch | ioSkeletal Myocytes
This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.
Article
Anthony Browne MP officially opens Cambridge headquarters
MP Anthony Browne visits bit.bio's labs and offices to officially open facilities.